Key Takeaways:
Sionna Therapeutics shares collapsed about 92% after its SION-719 cystic fibrosis trial missed its key sweat chloride endpoint.
Robbins Geller Rudman & Dowd and Levi & Korsinsky have opened securities investigations into whether Sionna adequately disclosed its reliance on the NBD1 stabilizer programs behind the failed candidate.
The Phase 2a PreciSION CF proof-of-concept trial produced a placebo-adjusted sweat chloride change of -1.0 mmol/L with a p-value of 0.7, and Sionna said it would not advance SION-719 as an add-on therapy. The clinical-stage biopharmaceutical company, which researches treatments for cystic fibrosis, held $268.3 million in cash, equivalents and marketable securities as of June 30, with a second-quarter net loss of $29.9 million.
Sionna disclosed the failure on Aug. 10, sending the stock down more than 91 percent in a single session. Its FY2025 10-K said it was "substantially dependent on the success of at least one of our NBD1 stabilizers," making the SION-719 setback a direct hit to its primary value driver. The investigations center on whether investors received adequate disclosure of that reliance and the risks tied to the program.
Robbins Geller, ranked No. 1 on the ISS Securities Class Action Services Top 50 report with $916 million recovered for investors in 2025, is urging investors and potential witnesses to come forward. Levi & Korsinsky, which has secured hundreds of millions of dollars for shareholders over two decades and employs more than 70 people, said eligibility depends on purchase date and documented losses, not on whether shares are still held.
The collapse leaves Sionna's pipeline without its lead add-on candidate and raises the prospect of shareholder litigation on top of the clinical setback. A securities class action, if filed, would seek to recover losses for investors who bought SION shares before the disclosure. Investors will watch for any update on the company's remaining NBD1 stabilizer programs and its cash runway as it reassesses strategy.
This article is for informational purposes only and does not constitute investment advice.
